|Bid||3.4000 x 900|
|Ask||4.0000 x 900|
|Day's Range||3.5339 - 3.7300|
|52 Week Range||2.1600 - 19.8000|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Sept 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.00|
SOPHiA GENETICS SA (Nasdaq: SOPH) ("the Company"), is pleased to announce the Annual General Meeting ("the Meeting") was held at the Company's headquarters, rue du Centre 172, 1025 St-Sulpice, VD, Switzerland, earlier today at 2:00 p.m. CET (8:00 a.m. EDT).
Steady Start to 2022; FY 2022 Constant Currency Revenue Growth Guidance ReaffirmedBOSTON, United States and LAUSANNE, Switzerland, May 10, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS SA (Nasdaq: SOPH), a leader in data-driven medicine, today reported financial results for the first quarter ended March 31, 2022. Recent Highlights Revenue for the first quarter of 2022 was $10.9 million, representing year-over-year revenue growth of 21%Constant currency revenue growth excluding COVID-19-related revenu
The big shareholder groups in SOPHiA GENETICS SA ( NASDAQ:SOPH ) have power over the company. Insiders often own a...